SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPDR S&P 500 ETF is surging as comments from Donald Trump about the Iran conflict being "very complete, pretty much" trigger a broad market rebound, though many in the community are highly skeptical, calling it a "Trump pump" or "manipulation" and questioning the true de-escalation given ongoing geopolitical tensions. The rapid turnaround has sparked intense debate over the market's current volatility and underlying catalysts.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting strong quarterly results driven by significant MIPLYFFA revenue, which exceeded expectations and signals a commercial breakthrough, fueling community discussions around future profitability, anticipated European approval, and the impact of a new CFO hire.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is surging, fueling a significant short squeeze, after reports of President Trump's optimistic statements suggested the Iran war is 'very complete, pretty much,' leading to a market rebound and a sharp drop in oil prices amid divided investor sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is highly volatile amid escalating Middle East tensions threatening global oil supply, while conflicting statements from former President Trump suggesting the conflict is "very complete" are causing sharp, contentious reversals. The market remains deeply divided on whether sustained geopolitical risks will outweigh potential de-escalation and strategic reserve releases.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as escalating geopolitical tensions, particularly concerning a potential conflict involving Iran and its impact on rising oil prices, are driving widespread market fear and discussions of increased volatility. The community is actively debating whether to accumulate UVIX as a hedge against a market correction or if these events are already priced into the market amid perceived manipulation.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is gaining attention following a new DOE agreement for its IMSR Fuel Salt production pilot and recent positive analyst coverage with a $15 price target. The community actively discusses its Integral Molten Salt Reactor technology as a "dark horse" in the advanced nuclear sector, comparing its potential to peers like OKLO, especially given its strategic position to meet escalating AI data center energy demands.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending amid heavy selling pressure, exacerbated by insider sales and a lowered analyst target, leading to a sharp community divide between those calling it a falling knife and those accumulating shares based on its long-term potential to power AI data centers, particularly following its Meta partnership.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 interim data for its bladder cancer candidate NDV-01, which supports advancing to Phase 3, alongside an oversubscribed $160 million private placement financing. The community is vigorously discussing the biotech's significant price and volume surge, anticipating continued momentum for its promising clinical pipeline.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is experiencing a massive price and volume surge as a short squeeze narrative takes hold, fueled by discussions around its recent private placement financing and updates to its lead candidate's Phase 3 trial status. Community sentiment is polarized between expectations of significant further gains and warnings of a pump-and-dump, reflecting the stock's historical volatility.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

HPE is trending as its recent earnings showcased strong demand for AI systems and significant growth in its networking segment, boosted by the completed Juniper Networks acquisition. The community is actively discussing the company's strategic shift to an AI-driven hybrid cloud and networking powerhouse, anticipating substantial market share gains despite lingering concerns about short-term outlooks and rising component costs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3% - Time to Sell?

Jyong Biotech (NASDAQ:MENS) Shares Down 12.3% - Here's Why...

Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 649,057 shares, an...

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) saw a significant increase in short interest in December. As of December 15th, there was short interest totaling 252,374 shares, an increase of...

Jyong Biotech (NASDAQ:MENS) Shares Gap Up - Still a Buy?

Jyong Biotech (NASDAQ:MENS) Shares Gap Up - Time to Buy...

Jyong Biotech (NASDAQ:MENS) Stock Price Down 19.3% - Here's What Happened

Jyong Biotech (NASDAQ:MENS) Shares Down 19.3% - Should You Sell...

Jyong Biotech (NASDAQ:MENS) Trading Down 5.9% - Here's Why

Jyong Biotech (NASDAQ:MENS) Shares Down 5.9% - Here's Why...

Jyong Biotech Ltd.'s (NASDAQ:MENS) Lock-Up Period Will End on December 15th

Jyong Biotech's (NASDAQ:MENS - Get Free Report) lock-up period will expire on Monday, December 15th. Jyong Biotech had issued 2,666,667 shares in its public offering on June 17th. The total size of...

Jyong Biotech (NASDAQ:MENS) Shares Gap Down - Here's Why

Jyong Biotech (NASDAQ:MENS) Shares Gap Down - Here's What Happened...

Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3% - Time to Sell?

Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3% - Here's Why...

Jyong Biotech (NASDAQ:MENS) Trading Up 15.1% - Here's What Happened

Jyong Biotech (NASDAQ:MENS) Trading 15.1% Higher - Should You Buy...

Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. It offers plant-derived drugs that focus on the treatment of urinary system diseases. The company was founded by Fu Feng Kuo in July 2002 and is headquartered in New Taipei, Taiwan.

MENS
Jyong Biotech Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest MENS News

MENSJyong Biotech Ltd.